Cabozantinib a Viable Choice for Non-Clear Cell Renal Cell Carcinoma
There are no biomarkers that have been prospectively validated to help predict which patients with non-clear cell RCC might respond to cabozantinib.
Renal Cell Carcinoma
Predicting PD-1/PD-L1 Immunotherapy Responses
Finding biomarkers that can broadly and reliably predict immunotherapy outcomes for patients with cancer remains an elusive “holy grail,” said Dr Ott.
Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
Concerns about conflict of interest as it relates to prescribing may never go away, some say, as long as drug companies offer doctors money for consulting and personal services.
Opinion: Understanding the FDA’s Take on Cannabidiol
In a statement announcing a newly created partnership, the Botanical Safety Consortium, FDA Commissioner Scott Gottlieb made no mention of cannabidiol.
Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
Compared with sorafenib, tivozanib was associated with improved progression-free survival and objective response rate, researchers reported.
First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
About 25% of patients with previously untreated advanced non-clear cell renal cell carcinoma had an objective response to pembrolizumab.
Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
New analysis shows that early tumor shrinkage with cabozantinib is associated with longer survival compared with everolimus.
Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
Avelumab-axitinib regimen offers better progression-free survival and responses than sunitinib for patients with previously untreated advanced RCC, regardless of risk group or PD-L1 status.
Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed
Patients with treatment-naive, intermediate- and poor-risk advanced RCC continue to have superior overall survival with the dual ICI regimen compared with sunitinib alone.
Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
As first-line therapy for locally advanced or metastatic renal cell carcinoma, pembrolizumab plus axitinib offers longer overall and progression-free survival compared with sunitinib.
Next post in Genitourinary Cancers Symposium 2019
